Evidence map›Paper›PMID 36808573›Full record

ArticleInternational microbiology : the official journal of the Spanish Society for Microbiology2023

Combination of Bifidobacterium breve and antibiotics against Clostridioides difficile: effect of the time interval of combination on antagonistic activity.

Jingpeng Yang, Yanan Li, Lingtong Meng

Abstract read
PubMed Publisher
In one paragraph

Article in International microbiology : the official journal of the Spanish Society for Microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jingpeng Yang *School of Food Science and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, China. yang_jp008@163.com.ORCID http://orcid.org/0000-0002-0802-2891
Yanan Li *School of Food Science and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, China.
Lingtong MengSchool of Food Science and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, China. mlt_nju@163.com.
Nanjing Normal University · CN

Funding

National Natural Science Foundation of China No. 32200154
6 · The paper itself

Abstract

Co-administration of probiotics and antibiotics has been used to prevent or treat primary Clostridioides difficile (pCDI), and the closer the interval between the combination, the more effective it is, but the reason behind this is unknown. In this study, the cell-free culture supernatant (CFCS) of Bifidobacterium breve YH68 was used in combination with vancomycin (VAN) and metronidazole (MTR) to treat C. difficile cells. The growth and biofilm production of C. difficile under different co-administration time interval treatments were determined by optical density and crystalline violet staining, respectively. The toxin production of C. difficile was determined by enzyme immunoassay, and the relative expressions of C. difficile virulence genes tcdA and tcdB were determined by real-time qPCR method. Meanwhile, the types and contents of organic acids in YH68-CFCS were investigated by LC-MS/MS. The results showed that YH68-CFCS in combination with VAN or MTR significantly inhibited the growth, biofilm production, and toxin production of C. difficile in the effective time interval range (0-12 h) but did not affect the expression level of C. difficile virulence genes. In addition, the effective antibacterial component of YH68-CFCS is lactic acid (LA).

Indexed as

Bacterial ToxinsBifidobacterium breveClostridioides difficileAnti-Bacterial AgentsBacterial ProteinsChromatography, LiquidClostridioidesEnterotoxinsMetronidazoleTandem Mass SpectrometryVancomycinAnti-Bacterial AgentsBacterial ProteinsBacterial ToxinsEnterotoxinsMetronidazoleVancomycinBifidobacterium breveClostridioides difficileMetronidazoleTime intervalVancomycin

Identifiers

PMID36808573
OpenAlexW4321351673

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.